Argenx Japan Launches Disease Awareness Activities for CIDP Awareness Month
Argenx Japan K.K. is launching disease awareness activities, including public lectures and manga videos, to deepen understanding of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) during its awareness month in May. The initiative aims to raise overall public recognition of CIDP, a designated intractable disease in Japan with an estimated 4,180 patients.
📋 Article Processing Timeline
- 📰 Published: May 8, 2026 at 23:00
- 🔍 Collected: May 8, 2026 at 14:31
- 🤖 AI Analyzed: May 8, 2026 at 15:26 (54 min after Collected)
Argenx Japan K.K. (Headquarters: Minato-ku, Tokyo; Representative Director and President: Taro Goto; hereinafter "Argenx Japan") will launch disease awareness activities, including public lectures and manga videos, to deepen understanding of "Chronic Inflammatory Demyelinating Polyneuropathy (hereinafter CIDP)" in conjunction with its awareness month in May.
Slogan Logo
CIDP, a designated intractable disease in Japan, causes muscle weakness and sensory impairment in the limbs due to inflammation of the peripheral nerves. According to a national epidemiological survey conducted in 2021, the estimated number of patients in Japan is 4,180. *1
These awareness activities will include holding public lectures inviting specialists and patients, and distributing manga videos depicting the importance of choosing a treatment method while sharing information with doctors, with a CIDP patient as the protagonist. Argenx Japan will actively promote activities to raise overall public awareness of CIDP.
【Activity Overview】
① CIDP Public Lecture
Under the slogan "Correct knowledge is power," this event aims to provide a forum for deepening understanding of the disease and its treatment through the dissemination of accurate knowledge about CIDP.
【Name】 Correct knowledge is power. CIDP Public Lecture for Patients
【Date】 Saturday, May 30, 2026, 13:00-14:45
【Venue】 Umeda South Hall Main Hall (Osaka) and online
【Participation Fee】 Free
【How to Participate】 Pre-registration required via website
【Website】 https://yab-lp.yomiuri.co.jp/yomidr/cidp2026/kansai/
【Speakers】
Dr. Motoi Kuwabara, Department of Neurology, Kinki University Faculty of Medicine
Dr. Yuko Yamagishi, Department of Neurology, Kinki University Faculty of Medicine
Ms. Mami Ukai, National CIDP Support Group
Ms. Natsuko Kojima, Freelance Announcer
【Content】
〈Keynote Lecture〉 What is CIDP? ~Diagnosis and Treatment You Should Know~
〈Doctor x Patient Session〉 Talking about the "Now" of CIDP. From noticing symptoms to dialogue in the examination room, and the reality of daily life.
【Contact】 CIDP Public Lecture Secretariat MAIL：registration@cpfine.biz
② Disease Awareness Manga Videos
Manga videos that clearly convey the importance of "SDM (Shared Decision Making)" – choosing the best treatment method for oneself while sharing information with a doctor, with a patient facing CIDP as the protagonist – will be distributed on our official YouTube channel.
Title 1 "Learning about CIDP with Manga Videos: About the Disease and Treatment" (Coming soon)
Title 2 "Learning about CIDP with Manga Videos: ~Checklist for Understanding Your Condition I-RODS~" (Scheduled for June release)
Official YouTube Channel: https://www.youtube.com/@argenxjapan
About Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CIDP is an immune-mediated demyelinating peripheral neuropathy primarily characterized by limb muscle weakness and sensory impairment. *2
Although the onset and pathogenesis are not fully understood, individual patients follow various courses, such as repeated relapses and remissions over a long period, and gradual or stepwise progression. *1
This disease causes various burdens, such as impaired motor function and activities of daily living, reduced QOL, and impact on employment.
About Argenx Japan K.K.
Argenx Japan K.K. is the Japanese subsidiary of Argenx BV, headquartered in Ghent, Belgium. Argenx is a global biopharmaceutical company specializing in immunology, committed to improving the lives of people suffering from severe autoimmune diseases. Through its unique Immunology Innovation Program (IIP), it collaborates with leading academic researchers to create a global portfolio of novel antibody drugs from groundbreaking discoveries in immunology.
Argenx has developed and commercialized the first approved anti-neonatal Fc receptor (FcRn) antibody fragment drug in the United States, Japan, Israel, the EU, the UK, Canada, Switzerland, China, and other countries. The company is also evaluating efgartigimod for many severe autoimmune diseases and is advancing early research and development for multiple new products in its focused therapeutic areas.
For more information about Argenx Japan, please visit www.argenx.jp.
References:
*1. Aotsuka Y, et al: Neurology. 2024; 102(6): e209130
*2. The Japanese Society of Neurology: Chronic Inflammatory Demyelinating Polyneuropathy, Multifocal Motor Neuropathy
Keywords:
Slogan Logo
CIDP, a designated intractable disease in Japan, causes muscle weakness and sensory impairment in the limbs due to inflammation of the peripheral nerves. According to a national epidemiological survey conducted in 2021, the estimated number of patients in Japan is 4,180. *1
These awareness activities will include holding public lectures inviting specialists and patients, and distributing manga videos depicting the importance of choosing a treatment method while sharing information with doctors, with a CIDP patient as the protagonist. Argenx Japan will actively promote activities to raise overall public awareness of CIDP.
【Activity Overview】
① CIDP Public Lecture
Under the slogan "Correct knowledge is power," this event aims to provide a forum for deepening understanding of the disease and its treatment through the dissemination of accurate knowledge about CIDP.
【Name】 Correct knowledge is power. CIDP Public Lecture for Patients
【Date】 Saturday, May 30, 2026, 13:00-14:45
【Venue】 Umeda South Hall Main Hall (Osaka) and online
【Participation Fee】 Free
【How to Participate】 Pre-registration required via website
【Website】 https://yab-lp.yomiuri.co.jp/yomidr/cidp2026/kansai/
【Speakers】
Dr. Motoi Kuwabara, Department of Neurology, Kinki University Faculty of Medicine
Dr. Yuko Yamagishi, Department of Neurology, Kinki University Faculty of Medicine
Ms. Mami Ukai, National CIDP Support Group
Ms. Natsuko Kojima, Freelance Announcer
【Content】
〈Keynote Lecture〉 What is CIDP? ~Diagnosis and Treatment You Should Know~
〈Doctor x Patient Session〉 Talking about the "Now" of CIDP. From noticing symptoms to dialogue in the examination room, and the reality of daily life.
【Contact】 CIDP Public Lecture Secretariat MAIL：registration@cpfine.biz
② Disease Awareness Manga Videos
Manga videos that clearly convey the importance of "SDM (Shared Decision Making)" – choosing the best treatment method for oneself while sharing information with a doctor, with a patient facing CIDP as the protagonist – will be distributed on our official YouTube channel.
Title 1 "Learning about CIDP with Manga Videos: About the Disease and Treatment" (Coming soon)
Title 2 "Learning about CIDP with Manga Videos: ~Checklist for Understanding Your Condition I-RODS~" (Scheduled for June release)
Official YouTube Channel: https://www.youtube.com/@argenxjapan
About Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CIDP is an immune-mediated demyelinating peripheral neuropathy primarily characterized by limb muscle weakness and sensory impairment. *2
Although the onset and pathogenesis are not fully understood, individual patients follow various courses, such as repeated relapses and remissions over a long period, and gradual or stepwise progression. *1
This disease causes various burdens, such as impaired motor function and activities of daily living, reduced QOL, and impact on employment.
About Argenx Japan K.K.
Argenx Japan K.K. is the Japanese subsidiary of Argenx BV, headquartered in Ghent, Belgium. Argenx is a global biopharmaceutical company specializing in immunology, committed to improving the lives of people suffering from severe autoimmune diseases. Through its unique Immunology Innovation Program (IIP), it collaborates with leading academic researchers to create a global portfolio of novel antibody drugs from groundbreaking discoveries in immunology.
Argenx has developed and commercialized the first approved anti-neonatal Fc receptor (FcRn) antibody fragment drug in the United States, Japan, Israel, the EU, the UK, Canada, Switzerland, China, and other countries. The company is also evaluating efgartigimod for many severe autoimmune diseases and is advancing early research and development for multiple new products in its focused therapeutic areas.
For more information about Argenx Japan, please visit www.argenx.jp.
References:
*1. Aotsuka Y, et al: Neurology. 2024; 102(6): e209130
*2. The Japanese Society of Neurology: Chronic Inflammatory Demyelinating Polyneuropathy, Multifocal Motor Neuropathy
Keywords: